Dr. Kamen is a venture partner at Third Rock Ventures. Prior to that, he served as an executive-in-residence at Oxford Bioscience Partners. Dr. Kamen’s career began as Senior VP Scientific Affairs at Genetics Institute, Inc., a pioneering biopharmaceutical firm that was acquired by Wyeth. He previously served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira, the first fully human antibody to achieve marketing approval in the U.S. and Europe and was a member of the Abbott Pharmaceuticals Executive Management Committee. He also was the president of the BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001.
Dr. Kamen is a co-founder of BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, that was acquired by Cephalon. Dr. Kamen serves as a director of Jounce Therapeutics, Harbour Biomed, and EpimAb Biotherapeutics. He previously served as a director at Neon Therapeutics, Harbour Antibodies, Lycera, Opsonic Therapeutics, and Anchor Therapeutics and was a member of the GlaxoSmithKline Biopharma Investment Board. Dr. Kamen received his undergraduate degree in biophysics from Amherst College (summa cum laude) and his Ph.D. in biochemistry and molecular biology from Harvard University.